ENGLEWOOD, Colo., August 2, 2018 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE: AMPE) a clinical trial stage
biopharmaceutical company primarily focused on the development of
therapies to treat prevalent inflammatory conditions for which
there are limited treatment options, today announced it will be
featured as a presenting company at the 38th Annual
Canaccord Genuity Growth Conference. The conference is being held
on August 8-9, 2018 at
InterContinental Boston in Boston,
Massachusetts. Tom Chilcott,
Chief Financial Officer, Michael
Macaluso, Chief Executive Officer, and Holli Cherevka, Chief Operating Officer will
provide an overview of the Company's business during the
presentation scheduled Wednesday, August 8,
2018, at 1:00 pm EDT.
Management will also be meeting with members of the investment
community during one-on-one meetings.
Event: Canaccord Genuity Growth Conference
Date: August 8, 2018
Time: 1:00pm – 1:25 pm (Eastern Time)
Location: InterContinental Boston
About Ampio Pharmaceuticals
Ampio Pharmaceuticals,
Inc. is a development stage biopharmaceutical company primarily
focused on the development of therapies to treat prevalent
inflammatory conditions for which there are limited treatment
options. We are developing compounds that decrease inflammation by
(i) inhibiting specific pro-inflammatory compounds by affecting
specific pathways at the protein expression and the transcription
level; (ii) activating specific phosphatase or depletion of the
available phosphate needed for the inflammation process; and (iii)
decreasing vascular permeability.
Forward-Looking Statements
Ampio's statements
in this press release that are not historical fact, and that relate
to future plans or events, are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
words such as "believe," "expect," "plan," "anticipate," and
similar expressions. These forward-looking statements include
statements regarding Ampio's expectations with respect to Ampion™,
as well as those associated with clinical trials, expected results,
regulatory approvals, the ability of Ampio to enter into partnering
arrangements, the Biological License Application (BLA) and
decisions and changes in business conditions and similar events,
all of which are inherently subject to various risks and
uncertainties. The risks and uncertainties involved include
those detailed from time to time in Ampio's filings with the
Securities and Exchange Commission, including without limitation,
under Ampio's Annual Report on Form 10-K and other documents filed
with the Securities and Exchange Commission. Ampio undertakes no
obligation to revise or update these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Company Contact
Tom
Chilcott
Chief Financial Officer
Tchilcott@ampiopharma.com
Phone: (720) 437-6500
View original content with
multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-present-at-the-38th-annual-canaccord-genuity-growth-conference-300690826.html
SOURCE Ampio Pharmaceuticals, Inc.